X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (717) 717
Patent (45) 45
Data Set (43) 43
Book / eBook (37) 37
Publication (26) 26
Conference Proceeding (18) 18
Book Review (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (300) 300
male (147) 147
middle aged (145) 145
female (141) 141
adult (139) 139
index medicus (128) 128
hematology (118) 118
oncology (109) 109
aged (87) 87
treatment outcome (62) 62
hematopoietic stem cells (56) 56
transplantation (55) 55
chemotherapy (49) 49
adolescent (46) 46
stem cells (43) 43
animals (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
cancer (38) 38
multidisciplinary sciences (37) 37
prognosis (37) 37
young adult (37) 37
chemistry (36) 36
hematopoietic stem cells - cytology (36) 36
metallurgy (36) 36
leukemia (35) 35
human necessities (34) 34
hygiene (34) 34
medical or veterinary science (34) 34
medicine & public health (34) 34
preparations for medical, dental, or toilet purposes (34) 34
survival (34) 34
time factors (32) 32
analysis (31) 31
hematopoietic stem cell transplantation (31) 31
specific therapeutic activity of chemical compounds ormedicinal preparations (30) 30
cell biology (29) 29
microbiology (29) 29
retrospective studies (29) 29
cells, cultured (28) 28
progenitor cells (28) 28
therapy (28) 28
risk factors (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
aged, 80 and over (24) 24
bone-marrow (24) 24
colony-stimulating factor (24) 24
culture media (24) 24
flow cytometry (24) 24
follow-up studies (24) 24
beer (23) 23
biochemistry (23) 23
enzymology (23) 23
mutation or genetic engineering (23) 23
spirits (23) 23
vinegar (23) 23
wine (23) 23
acute myeloid-leukemia (22) 22
hematopoiesis (22) 22
hematopoietic stem cell transplantation - methods (22) 22
hematopoietic stem cells - metabolism (22) 22
immunology (22) 22
in-vitro (22) 22
survival rate (22) 22
transplantation, homologous (22) 22
compositions thereof (21) 21
microorganisms or enzymes (21) 21
peptides (21) 21
propagating, preserving or maintaining microorganisms (21) 21
combined modality therapy (20) 20
disease (20) 20
mice (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (18) 18
care and treatment (18) 18
hematopoietic stem cells - drug effects (18) 18
high-dose chemotherapy (18) 18
bone-marrow transplantation (17) 17
germany (17) 17
hematopoietic stem cell transplantation - adverse effects (17) 17
hematopoietic stem cells - immunology (17) 17
risk (17) 17
abridged index medicus (16) 16
bone marrow (16) 16
dendritic cells (16) 16
dendritic cells - immunology (16) 16
disease-free survival (16) 16
hematopoietic progenitor cells (16) 16
imatinib mesylate (16) 16
immunotherapy (16) 16
organic chemistry (16) 16
rheumatology (16) 16
cisplatin (15) 15
differentiation (15) 15
hematopoietic stem cells - physiology (15) 15
research (15) 15
survival analysis (15) 15
transplantation, autologous (15) 15
versus-host-disease (15) 15
dose-response relationship, drug (14) 14
identification (14) 14
medicine, research & experimental (14) 14
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (18) 18
UTL at Downsview - May be requested (13) 13
UofT at Mississauga - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Gerstein Science - Stacks (1) 1
Royal Ontario Museum - Far Eastern (1) 1
Victoria University E.J. Pratt - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (794) 794
German (79) 79
French (15) 15
Spanish (2) 2
Chinese (1) 1
Danish (1) 1
Hebrew (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Annals of the New York Academy of Sciences, ISBN 9781573318679, Volume 1266, vii, 188
"Twenty-four invited speakers presented their data on basic and clinical research in the exciting and rapidly evolving field of stem cell biology. The... 
Hematopoietic stem cells
Book
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet, The, ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
SURVIVAL | FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | RITUXIMAB | COMBINATION | FLUDARABINE | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1036 - 1047
Summary Background High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma. The role of whole brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | DEFERRED RADIOTHERAPY | 1ST-LINE TREATMENT | ONCOLOGY-GROUP | COMBINED-MODALITY THERAPY | ONCOLOGY | CONSOLIDATION RADIOTHERAPY | CELL TRANSPLANTATION | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | CHEMOTHERAPY | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma - mortality | Antimetabolites, Antineoplastic - administration & dosage | Central Nervous System Neoplasms - radiotherapy | Lymphoma - drug therapy | Time Factors | Dose Fractionation | Female | Lymphoma - radiotherapy | Radiotherapy, Adjuvant | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Chi-Square Distribution | Cranial Irradiation - adverse effects | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Germany | Chemotherapy | Radiation | Product development | Lymphomas | Methotrexate | Radiotherapy | Biometry | Cancer
Journal Article
Journal Article
2016, Annals of the New York Academy of Sciences, Volume 1370., 125 pages
"Stemming from the ninth international symposium “Hematopoietic Stem Cells IX,” held and hosted by the University of Tübingen, Germany in April 2015, this... 
Hematopoietic stem cells
Book
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2015, Volume 112, Issue 2, pp. E166 - E175
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Journal Article